Quantum Biopharma Ltd. QNTM
3.85
(0.15)
(3.75%)
as of 25 Sep
- Market cap
- $30.9M
- P/E
- 0.0×
Follow QNTM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
P/S ratio |
— | — | — | — | — | — | 165.48 | 0.00 | — | — |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | — | — | — | — | (13.14) | 0.00 | — | — |
P/B ratio |
— | — | — | — | — | — | 1.06 | 0.00 | — | — |
Price to Tangible BV |
— | — | — | — | — | — | 1.97 | 0.00 | — | — |
EV/Sales |
— | — | — | — | — | — | 139.74 | 0.00 | — | — |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | — | — | — | — | (2.36) | 0.00 | — | — |
EV/FCF |
— | — | — | — | — | — | (2.29) | 0.00 | — | — |
Quick Ratio |
0.79 | 1.78 | 2.39 | 2.22 | 4.13 | 3.17 | 1.10 | 12.68 | 4.05 | 0.18 |
Current Ratio |
1.07 | 1.80 | 2.43 | 2.28 | 5.28 | 4.82 | 1.25 | 12.94 | 4.26 | 0.24 |
Net Debt/EBITDA |
0.31 | 0.52 | 0.17 | 0.74 | 1.19 | 0.65 | 0.29 | 0.65 | 1.36 | 0.17 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.31 | 0.48 | 0.60 | 1.20 | 0.59 | 0.60 | 0.35 | 0.81 | 0.04 | 0.42 |
Capex/Depreciation |
(5.74) | (2.04) | 0.00 | (0.08) | (0.12) | 0.00 | (0.36) | (22.02) | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (336.82%) | (121.65%) | (82.40%) | (55.76%) | (78.03%) | (87.62%) | (103.45%) | (67.67%) | (54.91%) | (2.76%) | |
| (185.11%) | (82.11%) | (64.07%) | (46.57%) | (67.25%) | (74.66%) | (93.24%) | (86.06%) | (998.87%) | (2.46%) | |
ROIC |
(1,823.10%) | (423.62%) | (158.24%) | (126.63%) | (112.70%) | (102.12%) | (46.36%) | (68.52%) | 0.00% | 0.00% |
Return on Tangible Assets |
(5,373.70%) | (260.57%) | (270.95%) | (233.14%) | (94.23%) | (149.39%) | (368.85%) | (68.89%) | (28.39%) | (41.67%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,934.51 | 4,039.51 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10,578.42% | 12,561.75% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.40 | 0.29 | 0.31 | 0.31 | 0.26 | 0.32 | 0.39 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,237.95% | 7,253.72% | — | — |
Graham Net Nets |
— | — | — | — | — | — | 0.04 | 0.00 | — | — |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | — | — | — | — | (96.26%) | (8.14%) | — | — |
Free Cash Flow Yield |
— | — | — | — | — | — | (36.80%) | 0.00% | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.78 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.51) | (6.05) | (17.78) | (47.50) | (38.55) | (103.13) | (126.15) | (0.78) | (0.03) | (0.01) |
Capex per Share |
(0.95) | (0.88) | 0.00 | (0.61) | (0.93) | 0.00 | (6.40) | (0.17) | 0.00 | 0.00 |
Free Cash Flow per Share |
(3.46) | (6.93) | (17.78) | (48.11) | (39.48) | (103.13) | (132.55) | (0.95) | (0.03) | (0.01) |
Cash per Share |
1.39 | 7.09 | 5.77 | 28.51 | 65.81 | 94.47 | 54.90 | 0.89 | 0.90 | 0.01 |
Shareholders Equity per Share |
1.55 | 9.18 | 21.20 | 51.20 | 100.58 | 195.73 | 333.74 | 2.15 | 2.32 | 0.08 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.55 | 9.18 | 21.20 | 51.20 | 100.58 | 195.73 | 333.74 | 2.15 | 2.32 | 0.08 |
Free Cash Flow |
(11.37) | (7.88) | (10.83) | (28.70) | (21.25) | (19.13) | (14.41) | (17.38) | (0.15) | (0.07) |
Working Capital |
0.42 | 5.37 | 6.52 | 10.02 | 37.23 | 21.29 | 1.73 | 16.07 | 4.12 | (0.21) |
Capital Expenditures |
(3.13) | (1.00) | — | (0.36) | (0.50) | — | (0.70) | (3.11) | (7.65) | — |
Net Current Asset Value |
0.42 | 5.37 | 6.52 | 9.98 | 37.10 | 21.21 | 1.62 | 16.07 | 4.12 | (0.21) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | — | 3.59 | 45.42 | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (20,201.08%) | (25,578.54%) | 0.00% | 0.00% |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
8.15 | 6.38 | 28.61 | 42.90 | 19.03 | 0.00 | 0.22 | 0.02 | 0.00 | 0.00 |
Cash ROIC |
(85.78%) | (37.59%) | (66.46%) | (59.81%) | (23.40%) | (35.54%) | (53.48%) | (42.45%) | (48.98%) | (156.97%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.13 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
2.02 | 5.61 | 3.90 | 0.44 | 0.33 | 0.86 | 1.16 | 0.53 | 0.17 | 0.17 |
Average Payables |
4.27 | 4.28 | 5.65 | 7.31 | 5.61 | 3.53 | 2.35 | 2.85 | — | — |
Average Inventory |
0.08 | 0.41 | — | — | — | — | — | — | — | — |
Average Assets |
14.14 | 17.30 | 27.94 | 50.69 | 52.47 | 42.59 | 41.97 | 20.36 | 0.35 | 7.19 |
Average Common Equity |
7.77 | 11.67 | 21.73 | 42.34 | 45.22 | 36.29 | 37.82 | 25.89 | 6.42 | 6.42 |
Columns are period end dates